#Taiwan #Germany #Frankfurt #Traditional Chinese Medicine #TCM

Taiwan's Traditional Chinese Medicine Pavilion at CPHI Frankfurt 2025

The Taiwan Pavilion dedicated to Traditional Chinese Medicine (TCM), led by the Department of Chinese Medicine and Pharmacy (DCMP) of the Ministry of Health and Welfare (MOHW), made a significant impact at CPHI Frankfurt 2025, which took place from October 28 to 30. This event marked the debut of Taiwan's first national TCM pavilion, spotlighting the country's growing research and development capabilities and its commitment to advancing evidence-based TCM globally.

During the three-day exhibition, the pavilion caught the attention of pharmaceutical professionals, distributors, and research institutions from around the world, who were eager to explore collaborative opportunities in product distribution and contract manufacturing (OEM/ODM). A total of 121 professional visitors engaged with Taiwan’s TCM enterprises, and the pavilion hosted four networking sessions involving five international companies and two business and investment organizations. This interaction generated new prospects for expanding into global markets.

Highlighting Taiwan’s achievements, the pavilion's participation in the CPHI Newsbeat stage marked a historic moment as it was the first time a Taiwanese exhibitor was selected for this global media platform. During this session, attendees received updates about Taiwan's evidence-based TCM development, followed by an interview with Raman Sehgal, host of the podcast "Molecule to Market," while representatives from approximately ten media outlets were present. This participation significantly enhanced Taiwan's visibility on the international scene.

Central to the discussions were NRICM101 and NRICM102, two renowned TCM formulas developed by the National Research Institute of Chinese Medicine, which have received endorsement from the MOHW. Supported by 11 peer-reviewed studies, these formulas have exhibited antiviral and anti-inflammatory properties, demonstrating their potential to reduce ICU admissions and mortality in COVID-19 patients while also providing protection against lung injury and cognitive dysfunction post-infection.

Exhibitors at the Taiwan Pavilion included Chuang Song Zong, Li Kang Biotech, Timing Pharmaceutical, Taiwan Three Mast, and Grape King Bio, showcasing the comprehensive ecosystem of Taiwan’s TCM industry, which encompasses clinical research, product innovation, GMP-certified manufacturing, and global OEM/ODM capabilities.

Throughout the event, Mei-Shun Lo, Director General of the Frankfurt am Main Office and Taipei Representative Office in Germany, alongside Bertram Roth, Vice President of FrankfurtRheinMain GmbH, met with the pavilion team. Both leaders expressed strong support for ground-breaking evidence-based collaboration in TCM and highlighted the promising potential of Taiwan's TCM industry in Europe, particularly Germany.

Dr. Yi-Chang Su, head of DCMP and NRICM, commented, "Taiwan's success at CPHI Frankfurt underscores our commitment to integrate proven Traditional Chinese Medicine into the global healthcare dialogue. We aim to leverage this momentum to enhance collaboration and innovation in TCM on an international level."